Oracle Health Sciences announced the availability of Oracle Health Sciences OutcomeLogix On Demand 3.0 a Web-based, scalable data collection system that enables life science companies and contract research organizations (CROs) to efficiently capture accurate therapy outcome information from health care providers, as well as patients in late-stage studies.
The newest version of the solution incorporates several features that help meet increasing requirements to improve product safety and demonstrate long-term treatment efficacy. New capabilities that address the increasingly larger, geographically dispersed, and patient-centered nature of observational studies include:
Featuring a flexible, Web-based architecture, Oracle Health Sciences OutcomeLogix On Demand 3.0 can be deployed quickly and easily to large numbers of sites and patients.
Oracle Health Sciences OutcomeLogix On Demand 3.0 is part of a comprehensive portfolio of Oracle Health Sciences Cloud Applications and is powered by the Oracle Health Sciences Cloud to help customers accelerate IT deployments, reduce resources required to maintain IT infrastructure, and gain a more predictable IT spending pattern.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.